Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,218.00
(
1.73%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
97.72
(
1.03%
)
Bitcoin
78,310.76
(
0.09%
)
News Focus
News Focus
Post# of 108195
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ignatiusrielly35 post# 27343

Monday, 07/24/2017 3:45:57 PM

Monday, July 24, 2017 3:45:57 PM

Post# of 108195
I'm talking about the relative slowness of a trial in the "adjuvant" setting, such as AIM2CERV, compared to a trial in the metastatic setting (where ADXS conducted its phase-2 trial in cervical cancer).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today